After standard dosage of piperacillin plasma concentrations of drug are subtherapeutic in burn patients.
Burn patients
Dosing simulation
In silico analyses
Pharmacokinetic
Piperacillin
Journal
Naunyn-Schmiedeberg's archives of pharmacology
ISSN: 1432-1912
Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol
Pays: Germany
ID NLM: 0326264
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
22
08
2018
accepted:
19
10
2018
pubmed:
29
10
2018
medline:
25
12
2019
entrez:
29
10
2018
Statut:
ppublish
Résumé
Infections are a major problem in patients with burn diseases. Mortality is high despite antibiotic therapy as studies are controversial concerning drug underdosing. The aims of this prospective, observational study were to monitor plasma concentrations of piperacillin during standard piperacillin/tazobactam treatment in 20 burn patients and 16 controls from the intensive care unit (ICU) and to optimize doses by in silico analyses. Piperacillin/tazobactam (4/0.5 g, tid) was administered over 0.5 h. Blood samples were taken at 1, 4, and 7.5 h after the end of the infusion. Free piperacillin plasma concentrations were determined. Pharmacokinetic parameters and in silico analysis results were calculated using the freeware TDMx. The primary target was defined as percentage of the day (fT
Identifiants
pubmed: 30368548
doi: 10.1007/s00210-018-1573-6
pii: 10.1007/s00210-018-1573-6
doi:
Substances chimiques
Anti-Bacterial Agents
0
Piperacillin, Tazobactam Drug Combination
157044-21-8
Banques de données
ClinicalTrials.gov
['NCT03335137']
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
229-241Références
Alharbi Z, Piatkowski A, Dembinski R, Reckort S, Grieb G, Kauczok J, Pallua N (2012) Treatment of burns in the first 24 hours: simple and practical guide by answering 10 questions in a step-by-step form. World J Emerg Surg 7:13. https://doi.org/10.1186/1749-7922-7-13
doi: 10.1186/1749-7922-7-13
pubmed: 22583548
pmcid: 3506488
Avni T, Levcovich A, Ad-El DD, Leibovici L, Paul M (2010) Prophylactic antibiotics for burns patients: systematic review and meta-analysis. BMJ 340:c241. https://doi.org/10.1136/bmj.c241
doi: 10.1136/bmj.c241
pubmed: 20156911
pmcid: 2822136
Barajas-Nava LA, López-Alcalde J, Roqué i Figuls M, Solà I, Bonfill Cosp X (2013) Antibiotic prophylaxis for preventing burn wound infection. Cochrane Database Syst Rev CD008738. https://doi.org/10.1002/14651858.CD008738.pub2
Bergan T (1981) Overview of acylureidopenicillin pharmacokinetics. Scand J Infect Dis Suppl 29:33–48
pubmed: 7031864
Blanchet B, Jullien V, Vinsonneau C, Tod M (2008) Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients. Clin Pharmacokinet 47:635–654. https://doi.org/10.2165/00003088-200847100-00002
doi: 10.2165/00003088-200847100-00002
pubmed: 18783295
Bourget P, Lesne-Hulin A, Le Reveillé R, Le Bever H, Carsin H (1996) Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother 40:139–145
doi: 10.1128/AAC.40.1.139
pubmed: 8787895
pmcid: 163072
Briscoe SE, McWhinney BC, Lipman J, Roberts JA, Ungerer JPJ (2012) A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 907:178–184. https://doi.org/10.1016/j.jchromb.2012.09.016
doi: 10.1016/j.jchromb.2012.09.016
pubmed: 23026224
Bulitta JB, Duffull SB, Kinzig-Schippers M, Holzgrabe U, Stephan U, Drusano GL, Sörgel F (2007) Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 51:2497–2507. https://doi.org/10.1128/AAC.01477-06
doi: 10.1128/AAC.01477-06
pubmed: 17485505
pmcid: 1913222
Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP (2014) Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations. J Antimicrob Chemother 69:176–179. https://doi.org/10.1093/jac/dkt300
doi: 10.1093/jac/dkt300
pubmed: 23869050
Cartotto R, Callum J (2012) A review of the use of human albumin in burn patients. J Burn Care Res 33:702–717. https://doi.org/10.1097/BCR.0b013e31825b1cf6
doi: 10.1097/BCR.0b013e31825b1cf6
pubmed: 23143614
Chim H, Tan BH, Song C (2007) Five-year review of infections in a burn intensive care unit: high incidence of Acinetobacter baumannii in a tropical climate. Burns 33:1008–1014. https://doi.org/10.1016/j.burns.2007.03.003
doi: 10.1016/j.burns.2007.03.003
pubmed: 17996555
Church D, Elsayed S, Reid O, Winston B, Lindsay R (2006) Burn wound infections. Clin Microbiol Rev 19:403–434. https://doi.org/10.1128/CMR.19.2.403-434.2006
doi: 10.1128/CMR.19.2.403-434.2006
pubmed: 16614255
pmcid: 1471990
Conil JM, Georges B, Fourcade O, Seguin T, Lavit M, Samii K, Houin G, Tack I, Saivin S (2007a) Assessment of renal function in clinical practice at the bedside of burn patients. Br J Clin Pharmacol 63:583–594. https://doi.org/10.1111/j.1365-2125.2006.02807.x
doi: 10.1111/j.1365-2125.2006.02807.x
pubmed: 17166188
Conil JM, Georges B, Lavit M, Laguerre J, Samii K, Houin G, Saivin S (2007b) A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation. Br J Clin Pharmacol 64:27–35. https://doi.org/10.1111/j.1365-2125.2007.02857.x
doi: 10.1111/j.1365-2125.2007.02857.x
pubmed: 17324245
pmcid: 2000604
Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1–10 quiz 11-12
doi: 10.1086/516284
pubmed: 9455502
Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM, Surviving Sepsis Campaign Management Guidelines Committee (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32:858–873
doi: 10.1097/01.CCM.0000117317.18092.E4
pubmed: 15090974
Demling RH (2005) The burn edema process: current concepts. J Burn Care Rehabil 26:207–227
doi: 10.1097/01.BCR.0000150302.71007.80
pubmed: 15879742
Doh K, Woo H, Hur J, Yim H, Kim J, Chae H, Han S, Yim DS (2010) Population pharmacokinetics of meropenem in burn patients. J Antimicrob Chemother 65:2428–2435. https://doi.org/10.1093/jac/dkq317
doi: 10.1093/jac/dkq317
pubmed: 20817742
Fachinformation Piperacillin/Tazobactam 4 g / 0,5 g Pulver zur Herstellung einer Infusionslösung (2015). https://wwwfachinfode/suche/fi/013311. Assessed August 2015
Felton TW, Roberts JA, Lodise TP, Guilder MV, Boselli E, Neely MN, Hope WW (2014) Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy. Antimicrob Agents Chemother 58:4094–4102. https://doi.org/10.1128/AAC.02664-14
doi: 10.1128/AAC.02664-14
pubmed: 24798288
pmcid: 4068511
Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG (2007) Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti-Infect Ther 5:365–383. https://doi.org/10.1586/14787210.5.3.365
doi: 10.1586/14787210.5.3.365
pubmed: 17547502
Guilabert P, Usúa G, Martín N, Abarca L, Barret JP, Colomina MJ (2016) Fluid resuscitation management in patients with burns: update. Br J Anaesth 117:284–296. https://doi.org/10.1093/bja/aew266
doi: 10.1093/bja/aew266
pubmed: 27543523
Jaruratanasirikul S, Sriwiriyajan S, Punyo J (2005) Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 49:1337–1339. https://doi.org/10.1128/AAC.49.4.1337-1339.2005
doi: 10.1128/AAC.49.4.1337-1339.2005
pubmed: 15793108
pmcid: 1068632
Jeon S, Han S, Lee J, Hong T, Paek J, Woo H, Yim D-S (2014) Population pharmacokinetic analysis of piperacillin in burn patients. Antimicrob Agents Chemother 58:3744–3751. https://doi.org/10.1128/AAC.02089-13
doi: 10.1128/AAC.02089-13
pubmed: 24752260
pmcid: 4068553
Li C, Du X, Kuti JL, Nicolau DP (2007) Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 51:1725–1730. https://doi.org/10.1128/AAC.00294-06
doi: 10.1128/AAC.00294-06
pubmed: 17307978
pmcid: 1855547
Mann EA, Baun MM, Meininger JC, Wade CE (2012) Comparison of mortality associated with sepsis in the burn, trauma, and general intensive care unit patient: a systematic review of the literature. Shock 37:4–16. https://doi.org/10.1097/SHK.0b013e318237d6bf
doi: 10.1097/SHK.0b013e318237d6bf
pubmed: 21941222
McKinnon PS, Paladino JA, Schentag JJ (2008) Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 31:345–351. https://doi.org/10.1016/j.ijantimicag.2007.12.009
doi: 10.1016/j.ijantimicag.2007.12.009
pubmed: 18313273
McManus AT, Mason AD, McManus WF, Pruitt BA (1985) Twenty-five year review of Pseudomonas aeruginosa bacteremia in a burn center. Eur J Clin Microbiol 4:219–223
doi: 10.1007/BF02013601
pubmed: 3924612
McWhinney BC, Wallis SC, Hillister T, Roberts JA, Lipman J, Ungerer JPJ (2010) Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 878:2039–2043. https://doi.org/10.1016/j.jchromb.2010.05.027
doi: 10.1016/j.jchromb.2010.05.027
pubmed: 20561826
Mir MA, Khurram MF, Khan AH (2017) What should be the antibiotic prescription protocol for burn patients admitted in the department of burns, plastic and reconstructive surgery. Int Wound J 14:194–197. https://doi.org/10.1111/iwj.12588
doi: 10.1111/iwj.12588
pubmed: 26968730
Mohd Hafiz A-A, Staatz CE, Kirkpatrick CMJ, Lipman J, Roberts JA (2012) Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics. Minerva Anestesiol 78:94–104
pubmed: 21730935
Patel BM, Paratz J, See NC, Muller MJ, Rudd M, Paterson D, Briscoe SE, Ungerer J, McWhinney BC, Lipman J, Roberts JA (2012) Therapeutic drug monitoring of beta-lactam antibiotics in burns patients--a one-year prospective study. Ther Drug Monit 34:160–164. https://doi.org/10.1097/FTD.0b013e31824981a6
doi: 10.1097/FTD.0b013e31824981a6
pubmed: 22406650
Rafla K, Tredget EE (2011) Infection control in the burn unit. Burns 37:5–15. https://doi.org/10.1016/j.burns.2009.06.198
doi: 10.1016/j.burns.2009.06.198
pubmed: 20561750
Roberts JA (2011) Using PK/PD to optimize antibiotic dosing for critically ill patients. Curr Pharm Biotechnol 12:2070–2079
doi: 10.2174/138920111798808329
pubmed: 21554211
Roberts JA, Kruger P, Paterson DL, Lipman J (2008) Antibiotic resistance--what’s dosing got to do with it? Crit Care Med 36:2433–2440. https://doi.org/10.1097/CCM.0b013e318180fe62
doi: 10.1097/CCM.0b013e318180fe62
pubmed: 18596628
Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J (2010) Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 36:332–339. https://doi.org/10.1016/j.ijantimicag.2010.06.008
doi: 10.1016/j.ijantimicag.2010.06.008
pubmed: 20685085
Roberts JA, Paul SK, Akova M, Bassetti M, de Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J, DALI Study, Roberts JA, Lipman J, Starr T, Wallis SC, Paul SK, Margarit Ribas A, de Waele JJ, de Crop L, Spapen H, Wauters J, Dugernier T, Jorens P, Dapper I, de Backer D, Taccone FS, Rello J, Ruano L, Afonso E, Alvarez-Lerma F, Gracia-Arnillas MP, Fernandez F, Feijoo N, Bardolet N, Rovira A, Garro P, Colon D, Castillo C, Fernado J, Lopez MJ, Fernandez JL, Arribas AM, Teja JL, Ots E, Carlos Montejo J, Catalan M, Prieto I, Gonzalo G, Galvan B, Blasco MA, Meyer E, del Nogal F, Vidaur L, Sebastian R, Garde PM, Martin Velasco MM, Zaragoza Crespo R, Esperatti M, Torres A, Montravers P, Baldesi O, Dupont H, Mahjoub Y, Lasocki S, Constantin JM, Payen JF, Martin C, Albanese J, Malledant Y, Pottecher J, Lefrant JY, Jaber S, Joannes-Boyau O, Orban C, Ostermann M, McKenzie C, Berry W, Smith J, Lei K, Rubulotta F, Gordon A, Brett S, Stotz M, Templeton M, Rhodes A, Ebm C, Moran C, Kaukonen KM, Pettila V, Dimopoulos G, Koulenti D, Xristodoulou A, Theodorou V, Kouliatsis G, Sertaridou E, Anthopoulos G, Choutas G, Rantis T, Karatzas S, Balla M, Papanikolaou M, Myrianthefs P, Gavala A, Fildisis G, Koutsoukou A, Kyriakopoulou M, Petrochilou K, Kompoti M, Michalia M, Clouva-Molyvdas FM, Gkiokas G, Nikolakopoulos F, Psychogiou V, Malliotakis P, Akoumianaki E, Lilitsis E, Koulouras V, Nakos G, Kalogirou M, Komnos A, Zafeiridis T, Chaintoutis C, Arvaniti K, Matamis D, Chaintoutis C, Kydona C, Gritsi-Gerogianni N, Giasnetsova T, Giannakou M, Soultati I, Chytas I, Antoniadou E, Antipa E, Lathyris D, Koukoubani T, Paraforou T, Spiropoulou K, Bekos V, Spring A, Kalatzi T, Nikolaou H, Laskou M, Strouvalis I, Aloizos S, Kapogiannis S, Soldatou O, Bassetti M, Adembri C, Villa G, Giarratano A, Maurizio Raineri S, Cortegiani A, Montalto F, Strano MT, Ranieri VM, Sandroni C, de Pascale G, Molin A, Pelosi P, Montagnani L, Urbino R, Mastromauro I, de Rosa FG, Ranieri VM, Cardoso T, Afonso S, Goncalves-Pereira J, Baptista JP, Akova M, Ozveren A (2014) DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072–1083. https://doi.org/10.1093/cid/ciu027
doi: 10.1093/cid/ciu027
pubmed: 24429437
Roberts JA, Abdul-Aziz MH, Davis JS, Dulhunty JM, Cotta MO, Myburgh J, Bellomo R, Lipman J (2016) Continuous versus intermittent β-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med 194:681–691. https://doi.org/10.1164/rccm.201601-0024OC
doi: 10.1164/rccm.201601-0024OC
pubmed: 26974879
Schleibinger M, Steinbach CL, Töpper C, Kratzer A, Liebchen U, Kees F, Salzberger B, Kees MG (2015) Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients. Br J Clin Pharmacol 80:525–533. https://doi.org/10.1111/bcp.12636
doi: 10.1111/bcp.12636
pubmed: 25808018
pmcid: 4574837
Shiu J, Wang E, Tejani AM, Wasdell M (2013) Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections. Cochrane Database Syst Rev CD008481. https://doi.org/10.1002/14651858.CD008481.pub2
Shorr AF (2009) Review of studies of the impact on gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med 37:1463–1469. https://doi.org/10.1097/CCM.0b013e31819ced02
doi: 10.1097/CCM.0b013e31819ced02
pubmed: 19242341
Sime FB et al (2017) Are standard doses of piperacillin in piperacillin/tazobactam regimens adequate for the management of febrile neutropenia? Answers from population pharmacokinetic modelling and Monte Carlo simulations. Antimicrob Agents Chemother. https://doi.org/10.1128/AAC.00311-17
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). Jama 315:801–810. https://doi.org/10.1001/jama.2016.0287
doi: 10.1001/jama.2016.0287
pubmed: 26903338
pmcid: 4968574
Sinnollareddy MG, Roberts MS, Lipman J, Roberts JA (2012) β-Lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review. Clin Exp Pharmacol Physiol 39:489–496. https://doi.org/10.1111/j.1440-1681.2012.05715.x
doi: 10.1111/j.1440-1681.2012.05715.x
pubmed: 22519600
Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Witebolle X, de Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F (2010) Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 14:R126. https://doi.org/10.1186/cc9091
doi: 10.1186/cc9091
pubmed: 20594297
pmcid: 2945087
Tagami T, Matsui H, Fushimi K, Yasunaga H (2016) Prophylactic antibiotics may improve outcome in patients with severe burns requiring mechanical ventilation: propensity score analysis of a Japanese Nationwide Database. Clin Infect Dis 62:60–66. https://doi.org/10.1093/cid/civ763
doi: 10.1093/cid/civ763
pubmed: 26405146
Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL (2002) Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 50:425–428
doi: 10.1093/jac/dkf130
pubmed: 12205070
Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA (2005) Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother 49:4920–4927. https://doi.org/10.1128/AAC.49.12.4920-4927.2005
doi: 10.1128/AAC.49.12.4920-4927.2005
pubmed: 16304153
pmcid: 1315965
TDMx - model-supported Therapeutic Drug Monitoring for Precision Dosing (2017). http://www.tdmx.eu/ . Assessed Nov 2017
The European Committee on Antimicrobial Susceptibility Testing - EUCAST (2017). http://www.eucast.org/clinical_breakpoints/ . Assessed Oktober 2017
Tredget EE, Shankowsky HA, Rennie R, Burrell RE, Logsetty S (2004) Pseudomonas infections in the thermally injured patient. Burns 30:3–26
doi: 10.1016/j.burns.2003.08.007
pubmed: 14693082
Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, Lipman J, Roberts JA (2012) Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 142:30–39. https://doi.org/10.1378/chest.11-1671
doi: 10.1378/chest.11-1671
pubmed: 22194591
Udy AA, Lipman J, Jarrett P, Klein K, Wallis SC, Patel K, Kirkpatrick C, Kruger PS, Paterson DL, Roberts MS, Roberts JA (2015) Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance? Crit Care 19:28. https://doi.org/10.1186/s13054-015-0750-y
doi: 10.1186/s13054-015-0750-y
pubmed: 25632974
pmcid: 4341874
Vardakas KZ, Voulgaris GL, Maliaros A, Samonis G, Falagas ME (2018) Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis 18:108–120. https://doi.org/10.1016/S1473-3099(17)30615-1
doi: 10.1016/S1473-3099(17)30615-1
pubmed: 29102324
Weinbren MJ (1999) Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother 44:319–327. https://doi.org/10.1093/jac/44.3.319
doi: 10.1093/jac/44.3.319
pubmed: 10511398
Wicha SG, Kees MG, Solms A, Minichmayr IK, Kratzer A, Kloft C (2015) TDMx: a novel web-based open-access support tool for optimising antimicrobial dosing regimens in clinical routine. Int J Antimicrob Agents 45:442–444. https://doi.org/10.1016/j.ijantimicag.2014.12.010
doi: 10.1016/j.ijantimicag.2014.12.010
pubmed: 25631677
Witkowski W, Kawecki M, Surowiecka-Pastewka A, Klimm W, Szamotulska K, Niemczyk S (2016) Early and late acute kidney injury in severely burned patients. Med Sci Monit 22:3755–3763
doi: 10.12659/MSM.895875
pubmed: 27746455
pmcid: 5070618
Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lipman J, Roberts JA (2013) Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother 57:6165–6170. https://doi.org/10.1128/AAC.00951-13
doi: 10.1128/AAC.00951-13
pubmed: 24080664
pmcid: 3837907
Yoshino Y, Ohtsuka M, Kawaguchi M, Sakai K, Hashimoto A, Hayashi M, Madokoro N, Asano Y, Abe M, Ishii T, Isei T, Ito T, Inoue Y, Imafuku S, Irisawa R, Ohtsuka M, Ogawa F, Kadono T, Kawakami T, Kukino R, Kono T, Kodera M, Takahara M, Tanioka M, Nakanishi T, Nakamura Y, Hasegawa M, Fujimoto M, Fujiwara H, Maekawa T, Matsuo K, Yamasaki O, le Pavoux A, Tachibana T, Ihn H, The Wound/Burn Guidelines Committee (2016) The wound/burn guidelines - 6: guidelines for the management of burns. J Dermatol 43:989–1010. https://doi.org/10.1111/1346-8138.13288
doi: 10.1111/1346-8138.13288
pubmed: 26971391